Small molecule · Inhibitor · developed by Quoin Pharmaceuticals
QRX003 is a topical lotion containing a serine protease inhibitor at 2% or 4% active drug. It is studied in Netherton syndrome, a rare inherited skin disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07538583 | Phase 2/3 | Netherton Syndrome | Recruiting | QNRX |
| NCT06953466 | Phase 2/3 | Netherton Syndrome | Recruiting | QNRX |
| NCT05521438 | Phase 2/3 | Netherton Syndrome | Active not recruiting | QNRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Netherton Syndrome
Updated Oct 25, 2026. Something wrong or missing? Report it on the QNRX page.
See QNRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
QNRX catalysts and pipeline →